FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3022609614> ?p ?o ?g. }

• W3022609614 endingPage "155" @default.
• W3022609614 startingPage "143" @default.
• W3022609614 abstract "Abstract Ulcerative colitis (UC) is a chronic inflammatory disease characterized by diffused inflammation of the colon and rectum mucosa. The pathogenesis of UC is multifactorial, and the exact underlying mechanisms remain poorly understood. This study aims to investigate the effect of mesalazine and atorvastatin combination in enhancing anti‐inflammatory effects and attenuates progression of oxazolone colitis in rats. In the present study, male albino rats ( N = 60) were divided into six groups (10 rats each), the first two groups served as normal control and a control saline group. Colitis was induced by intra‐rectal administration of oxazolone in the 5th and 7th days after pre‐sensitization. Then, rats were divided into untreated group, groups treated with mesalazine or atorvastatin or their combination. Colitis was assessed by colon length, body weight, and incidence of diarrhea, rectal bleeding, and histopathology of colon tissue. Colon tissues were used for measuring interleukin 6 (IL‐6), tumor necrosis factor alpha (TNF‐α), IL‐13 , signal transducer and activator of transcription‐3 (STAT‐3), myeloperoxidase activity (MPO), reduced glutathione(GSH), and tissue expression of IL‐10, tight junction protein zonula occludens (ZO‐1), and caspase‐3 genes. The combination therapy significantly attenuated progression of UC by decreasing incidence of diarrhea, rectal bleeding, weight loss, IL‐13, IL‐6, TNF‐α, STAT‐3, caspase‐3, and MPO activity and significantly increased IL‐10, ZO‐1, colon length, and GSH content, and these effects were more superior to single drugs. These findings showed that combination therapy was able to ameliorate progression of UC and enhance anti‐inflammatory effects possibly by restoring IL‐10 and ZO‐1 levels and limiting IL‐6/STAT‐3 trans‐signaling." @default.
• W3022609614 created "2020-05-13" @default.
• W3022609614 creator A5021116443 @default.
• W3022609614 creator A5057265918 @default.
• W3022609614 creator A5060425439 @default.
• W3022609614 creator A5090306189 @default.
• W3022609614 date "2020-06-24" @default.
• W3022609614 modified "2023-10-18" @default.
• W3022609614 title "Targeting IL‐10, ZO‐1 gene expression and IL‐6/STAT‐3 trans‐signaling by a combination of atorvastatin and mesalazine to enhance anti‐inflammatory effects and attenuates progression of oxazolone‐induced colitis" @default.
• W3022609614 cites W1525331105 @default.
• W3022609614 cites W1553291301 @default.
• W3022609614 cites W1775749144 @default.
• W3022609614 cites W1847449663 @default.
• W3022609614 cites W1967655558 @default.
• W3022609614 cites W1994676778 @default.
• W3022609614 cites W2001913850 @default.
• W3022609614 cites W2006370393 @default.
• W3022609614 cites W2007606465 @default.
• W3022609614 cites W2008443866 @default.
• W3022609614 cites W2017749666 @default.
• W3022609614 cites W2023570621 @default.
• W3022609614 cites W2024255214 @default.
• W3022609614 cites W2026152618 @default.
• W3022609614 cites W2039881666 @default.
• W3022609614 cites W2048623692 @default.
• W3022609614 cites W2048938982 @default.
• W3022609614 cites W2055333102 @default.
• W3022609614 cites W2061114102 @default.
• W3022609614 cites W2061337084 @default.
• W3022609614 cites W2075762190 @default.
• W3022609614 cites W2082626794 @default.
• W3022609614 cites W2091431142 @default.
• W3022609614 cites W2093135927 @default.
• W3022609614 cites W2105269215 @default.
• W3022609614 cites W2107277218 @default.
• W3022609614 cites W2127501317 @default.
• W3022609614 cites W2137537116 @default.
• W3022609614 cites W2146367607 @default.
• W3022609614 cites W2146669088 @default.
• W3022609614 cites W2148199912 @default.
• W3022609614 cites W2156953890 @default.
• W3022609614 cites W2170211768 @default.
• W3022609614 cites W2190256747 @default.
• W3022609614 cites W2318276736 @default.
• W3022609614 cites W2416368848 @default.
• W3022609614 cites W2424946527 @default.
• W3022609614 cites W2517282160 @default.
• W3022609614 cites W2532623505 @default.
• W3022609614 cites W2555820897 @default.
• W3022609614 cites W2623188440 @default.
• W3022609614 cites W2734907482 @default.
• W3022609614 cites W2740876150 @default.
• W3022609614 cites W2765452809 @default.
• W3022609614 cites W2770222974 @default.
• W3022609614 cites W2770627674 @default.
• W3022609614 cites W2789519700 @default.
• W3022609614 cites W2794552175 @default.
• W3022609614 cites W2799955645 @default.
• W3022609614 cites W2891582884 @default.
• W3022609614 cites W2905312073 @default.
• W3022609614 cites W2908982911 @default.
• W3022609614 cites W2913001463 @default.
• W3022609614 cites W2915510829 @default.
• W3022609614 cites W2922295822 @default.
• W3022609614 cites W2963415738 @default.
• W3022609614 cites W2967912047 @default.
• W3022609614 cites W2968522152 @default.
• W3022609614 cites W2997931807 @default.
• W3022609614 cites W3003833992 @default.
• W3022609614 cites W3011348482 @default.
• W3022609614 cites W3036822282 @default.
• W3022609614 cites W4211138554 @default.
• W3022609614 cites W4251972739 @default.
• W3022609614 cites W2796638063 @default.
• W3022609614 cites W2926712093 @default.
• W3022609614 doi "https://doi.org/10.1111/fcp.12563" @default.
• W3022609614 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32383169" @default.
• W3022609614 hasPublicationYear "2020" @default.
• W3022609614 type Work @default.
• W3022609614 sameAs 3022609614 @default.
• W3022609614 citedByCount "11" @default.
• W3022609614 countsByYear W30226096142020 @default.
• W3022609614 countsByYear W30226096142021 @default.
• W3022609614 countsByYear W30226096142022 @default.
• W3022609614 countsByYear W30226096142023 @default.
• W3022609614 crossrefType "journal-article" @default.
• W3022609614 hasAuthorship W3022609614A5021116443 @default.
• W3022609614 hasAuthorship W3022609614A5057265918 @default.
• W3022609614 hasAuthorship W3022609614A5060425439 @default.
• W3022609614 hasAuthorship W3022609614A5090306189 @default.
• W3022609614 hasConcept C126322002 @default.
• W3022609614 hasConcept C164027704 @default.
• W3022609614 hasConcept C171958077 @default.
• W3022609614 hasConcept C17991360 @default.
• W3022609614 hasConcept C190283241 @default.
• W3022609614 hasConcept C203014093 @default.
• W3022609614 hasConcept C203565725 @default.
• W3022609614 hasConcept C2775862500 @default.

• next